New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

    NEXT STORY
    Fishawack Health Acquires Both The Hive Health Group and StoneArch
    PREV STORY
    Crohn’s and Colitis Canada Celebrates the 10th Anniversary of the AbbVie IBD Scholarship Program
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

    This three-way crossover study will inform design of pivotal Phase 3 trials  Top line ...

    author_avatar
    NASDAQ Market News

    Caladrius Biosciences Reports 2018 Third Quarter Financial Results

    Development programs remain on track accompanied by continued strong fiscal management Conference call begins ...

    author_avatar
    NASDAQ Market News

    Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal

    MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue ...

    author_avatar
    NASDAQ Market News